期刊文献+

原发性肺癌卫生经济学评价模型结构研究 被引量:6

Construction of Economic Evaluations Models for the Treatment of Lung Cancer
原文传递
导出
摘要 [目的]卫生经济学评价模型是在肺癌相关卫生经济学评价中广泛使用的技术,全文主要阐述了已有研究中肺癌评价模型的共性和个性规律。[方法]系统检索国内外已发表的肺癌卫生经济学评价文献,比较分析不同研究中模型架构的特点,对文献中出现的决策树模型、马尔可夫模型、分区生存模型进行解析和比较。[结果]共纳入24篇国内外肺癌经济学评价文献,马尔可夫模型最常见,不同的研究在3状态的基础上发展出4、5、6甚至更多状态的模型以突出技术特点。马尔可夫决策模型适用于个体化决策治疗,以辅助决策不同治疗方案的经济性。分区生存模型架构一般为3个状态,常用于晚期或转移性癌症干预的评价。[结论]不同模型类型和结构对应于不同研究设计,应以合理反映疾病进程、符合所研究卫生技术的特点为目的来构建。 [Purpose]To describe and summarize the construction of economic evaluation models for the treatment of lung cancer.[Methods]In this study we reviewed the decision tree models,Markov models and partitioned survival models for lung cancer treatment based on systematic literature review.[Results]Twenty-four studies were included according to the inclusion and exclusion criteria.Markov model was used more widely than decision tree model and partitioned survival model.Different Markov models have been developed with 4,5,6 or more states according to the characteristics of medical technologies analyzed.Markov model is usually used to evaluate different therapeutic strategies for lung cancer in general;while partitioned survival model,with 3 states mostly,is usually used for treatment of advanced or metastatic lung cancer.[Conclusion]The structure of economic evaluation model should be constructed according to the disease pro-cess and the medical techniques used.
作者 陈丽萍 陶立波 CHEN Li-ping;TAO Li-bo(School of Pharmaceutical Sciences,Sun Yat-sen University,Guangzhou 510006,China;Peking University Health Science Center,Beijing 100191,China)
出处 《中国肿瘤》 CAS CSCD 北大核心 2020年第4期278-284,共7页 China Cancer
关键词 肺肿瘤 卫生经济学评价 模型 lung neoplasms health economic evaluation model
  • 相关文献

参考文献6

二级参考文献24

  • 1杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1450
  • 2马建辉.重视实体瘤疗效评价标准的变革——RECIST概要[J].中华泌尿外科杂志,2006,27(2):77-79. 被引量:39
  • 3王梅,王媛媛,郭斌,郑建国,屈婉莹,姚稚明,罗志福,管一晖,王全师,高硕,张永学,尹吉林,黄庆娟,李亚明,刘庆伟,郭万华.我国肺癌疾病的直接住院费用负担现状及其问题[J].中国卫生经济,2007,26(6):59-62. 被引量:46
  • 4Inadomi JM.Decision analysis and economic modelling:a primer[J].Eur J Gastroenterol Hepatol,2004,16(6):535-542.
  • 5WHO handbook for reporting results of cancer treatment [ M ]. Offset Publi- cation : Geneva (Switzerland). World Health Organization, 1979.
  • 6Asukai Y,Valladares A,Camps C,et al.Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain:results for the non-squamous histology population[J].BMC Cancer,2010,10:26.
  • 7Beck JR,Kassirer JP,Pauker SG.A convenient approximation of life expectancy (The "DEALE")-I.Validation of the method[J].The American journal of medicine,1982,73:883-888.
  • 8Beck JR,Pauker SG,Gottlieb JE,et al.A convenient approximation of life expectancy (The "DEALE")-II.Use in medical decision-making[J].The American journal of medicine,1982,73:889-897.
  • 9Petitti DB.Meta-analysis,decision analysis and cost-effectiveness analysis[J].Oxford University press,2000:154.
  • 10Nafees B,Stafford M,Gavriel S,et al.Health state utilities for non-small cell lung cancer[J].Health and Quality of Life Outcomes,2008,6:84.

共引文献1056

同被引文献66

引证文献6

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部